Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Cetuximab in Advanced Squamous Cell Cancers of the Head and Neck
NCT02979977Phase 2Completed
- Sponsor
- Yale University
- Start
- Mar 2017
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and KL-140 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Yale University. Primary endpoint: Tumor Shrinkage up to 2 years. Started Mar 2017; status: completed.
02
Drugs
afatinibKL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02979977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979977.